Immunological Characterization and Therapeutic Activity of an Altered-Peptide Ligand, NBI-6024, Based on the Immunodominant Type 1 Diabetes Autoantigen Insulin B-Chain (9–23) Peptide - Alleva, David G.; Gaur, Amitabh; Jin, Liping; Wegmann, Dale; Gottlieb, Peter A.; Pahuja, Anil; Johnson, Eric B.; Motheral, Theresa; Putnam, Amy; Crowe, Paul D.; Ling, Nicholas; Boehme, Stefen A.; et al. (Diabetes (New York, N.Y.), 2002)
Keywords: Amino Acid Substitution; Animals; Autoantigens - blood; Biological and medical sciences; Cells, Cultured; Clone Cells; Development and progression; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - immunology; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Humans; Hypoglycemic Agents - pharmacology; Insulin - immunology; Insulin - pharmacology; Ligands; Lymphocyte Activation - drug effects; Medical sciences; Mice; Mice, Inbred NOD; Peptide Fragments - immunology; Peptide Fragments - pharmacology; Spleen - drug effects; Spleen - immunology; T-Lymphocytes - immunology; Type 1 diabetes; United States; Endocrinopathy; Characterization; Immunopathology; Pancreatic hormone; Autoantigen; Peptide fragment; Ligand; Insulin dependent diabetes; Autoimmune disease; Insulin